Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Abstract Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.

[1]  K. Rabe,et al.  Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review , 2018, Chest.

[2]  T. Sterling,et al.  American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy , 2006 .

[3]  K. Ohta,et al.  Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  R. Wallace,,et al.  Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. , 2005, American journal of respiratory and critical care medicine.

[5]  R. Wallace,,et al.  Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  S. Shin,et al.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease , 2016, Antimicrobial Agents and Chemotherapy.

[7]  William Girard,et al.  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.

[8]  K. Winthrop,et al.  Variable agreement among experts regarding Mycobacterium avium complex lung disease , 2015, Respirology.

[9]  W. Hoefsloot,et al.  Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. , 2017, Respiratory medicine.

[10]  C. Ki,et al.  Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. , 2015, American journal of respiratory and critical care medicine.

[11]  T. Betsuyaku,et al.  Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. , 2016, Annals of the American Thoracic Society.

[12]  J. Yim,et al.  Amikacin Liposome Inhalation Suspension for Treatment‐Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open‐Label, Randomized Study , 2018, American journal of respiratory and critical care medicine.

[13]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[14]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.